Table 6 shows the general pathologic response rates by molecular subtypes and axillary lymph node status. In HER2(+) BC patients, a 30% pCR response was achieved with the combination of trastuzumab and CTx, while a 67% pCR response was achieved with a dual anti-HER2 blockade and CTx (p = 0.007) (Table S1a). This evidence concerns the gene ERBB2 and breast cancer.